% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Mock:148366,
      author       = {A. Mock$^*$ and C. E. Heilig$^*$ and S. Kreutzfeldt$^*$ and
                      D. Huebschmann$^*$ and C. Heining$^*$ and E. Schröck$^*$
                      and B. Brors$^*$ and A. Stenzinger$^*$ and D. Jäger$^*$ and
                      R. Schlenk$^*$ and H. Glimm$^*$ and S. Fröhling$^*$ and P.
                      Horak$^*$ and L. Apostolidis and M. Augustin and D. Aust and
                      I. A. Bhatti and J. Bloehdorn and C. Brendel and C.
                      Britschgi and J. Braess and S. Burdach and E. Busch and J.
                      Casuscelli and A. Desuki and T. Deutsch and M. Dietrich and
                      U. Ehmer and T. J. Ettrich and J. Falkenhorst and T. Fehm
                      and A. Flörcken and A. Forschner and S. Fuxius and M.
                      Gonzales-Carmona and F. Griesinger and S. Grill and S.
                      Gröschel and G. M. Haag and U. Haag and N. Halama and H.
                      Hebart and N. Heidger and B. Hermes and G. Hess and S.
                      Hettmer and M. Hoechstetter and M. Hoffmann and F. J.
                      Hüttner and A. L. Illert and M. Jenzer and B. Kasper and S.
                      Kasper-Virchow and T. Kindler and E. Koscielniak and J.
                      Krönke and M. Kühn and V. Kunzmann and A. Lang and J.
                      Leichsenring and E. Livingstone and L. Liotta and K. Luley
                      and E. Mack and U. M. Martens and K. Metzeler and J. M.
                      Middeke and L. Möhrmann and R. Jayarama-Naidu and U.-F.
                      Pape and L. Perkhofer and A. Pfeufer and C. Pixberg and M.
                      Quante and B. Rendenbach and D. Rieke and C. Rothermundt and
                      A. N. Sagerer and M. Salzmann and D. Saur and B. Schilling
                      and J. Schleicher and A. Schlenska-Lange and T. Schmidt and
                      S. Schmitz and S. Schölch and R. Shah and K. Shoumariyeh
                      and A. Siebenhüner and M. Singh and J. Siveke and C.
                      Springfeld and H. Starke and S. Strobel and V. Teleanu and
                      N. Thon and S. Wagner and T. Walle and B. Westphalen and B.
                      Whitlock and E. Winkler and N. M. Wirsik and L. Woydack and
                      A. Z. Bois and S. Zschäbitz},
      collaboration = {D. M. Network},
      title        = {{C}ommunity-driven development of a modified
                      progression-free survival ratio for precision oncology.},
      journal      = {ESMO open},
      volume       = {4},
      number       = {6},
      issn         = {2059-7029},
      address      = {London},
      publisher    = {BMJ},
      reportid     = {DKFZ-2019-02922},
      pages        = {e000583},
      year         = {2019},
      abstract     = {Measuring the success of molecularly guided therapies is a
                      major challenge in precision oncology trials. A commonly
                      used endpoint is an intra-patient progression-free survival
                      (PFS) ratio, defined as the PFS interval associated with
                      molecularly guided therapy (PFS2) divided by the PFS
                      interval associated with the last prior systemic therapy
                      (PFS1), above 1.3 or, in some studies, above 1.33 or 1.5.To
                      investigate if the concept of PFS ratios is in agreement
                      with actual response evaluations by physicians, we conducted
                      a survey among members of the MASTER (Molecularly Aided
                      Stratification for Tumor Eradication Research) Programme of
                      the German Cancer Consortium who were asked to classify the
                      success of molecularly guided therapies in 194 patients
                      enrolled in the MOSCATO 01 trial based on PFS1 and PFS2
                      times.A comparison of classification profiles revealed three
                      distinct clusters of PFS benefit assessments. Only $29\%$ of
                      assessments were consistent with a PFS ratio threshold of
                      1.3, whereas the remaining $71\%$ of participants applied a
                      different classification scheme that did not rely on the
                      relation between PFS times alone, but also took into account
                      absolute PFS1 intervals. Based on these community-driven
                      insights, we developed a modified PFS ratio that
                      incorporates the influence of absolute PFS1 intervals on the
                      judgement of clinical benefit by physicians. Application of
                      the modified PFS ratio to outcome data from two recent
                      precision oncology trials, MOSCATO 01 and WINTHER, revealed
                      significantly improved concordance with physician-perceived
                      clinical benefit and identified comparable proportions of
                      patients who benefited from molecularly guided therapies.The
                      modified PFS ratio may represent a meaningful clinical
                      endpoint that could aid in the design and interpretation of
                      future precision oncology trials.},
      cin          = {B340 / L101 / V960 / L301 / D120 / B330},
      ddc          = {610},
      cid          = {I:(DE-He78)B340-20160331 / I:(DE-He78)L101-20160331 /
                      I:(DE-He78)V960-20160331 / I:(DE-He78)L301-20160331 /
                      I:(DE-He78)D120-20160331 / I:(DE-He78)B330-20160331},
      pnm          = {314 - Tumor immunology (POF3-314)},
      pid          = {G:(DE-HGF)POF3-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31798980},
      pmc          = {pmc:PMC6863673},
      doi          = {10.1136/esmoopen-2019-000583},
      url          = {https://inrepo02.dkfz.de/record/148366},
}